Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
-$0.11 today
- Market cap
- $426.53M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
Volume 2.16M
Average 3.07M
OVID Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Ovid Therapeutics Inc.NASDAQ: OVID
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 234.5% from a year ago
Total equity stood at $198.27M at the end of Q1 FY2026, up 234.5% from a year earlier and up 51.7% from the prior quarter. Over 3 fiscal years it compounded at -0.4% a year.
Context
- Total equity amounted to 87.9% of total assets at the end of Q1 FY2026, up 15.3 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +234.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 130.66M USD
- Year-over-year change
- +91.5%
- 4-year CAGR
- -7.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 130.66M | +91.5% |
| FY2024 | 2024-12-31 | 68.23M | -22.3% |
| FY2023 | 2023-12-31 | 87.8M | -33.6% |
| FY2022 | 2022-12-31 | 132.27M | -26.4% |
| FY2021 | 2021-12-31 | 179.75M | — |
Total Equity vs competitors
How OVID compares with its peers on the latest reported figures
- OVID's Mar 2026 total equity of $198.27M is the 7th highest of the 11 companies compared; the peer median is $234.64M.
- Its year-over-year change of +234.5% is the 2nd highest of 11, against a peer median of -2.9%.
- Total equity amounts to 87.9% of total assets for OVID, versus a peer median of 82.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $511.73M | +197.9% | — | 87.7% | |
| Mar 2026 | $394.88M | +12.8% | +24.0% | 89.1% | |
| Jun 2026 | $387.27M | +55.7% | +538.4% | 82.3% | |
| Mar 2026 | $238.04M | -42.2% | -17.3% | 83.4% | |
| Mar 2026 | $237.78M | -18.5% | +39.0% | 90.4% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $231.5M | +162.7% | — | 92.5% |
| Mar 2026 | $198.27M | +234.5% | -0.4% | 87.9% | |
| Mar 2026 | $173.67M | -36.3% | +49.2% | 79.2% | |
| Mar 2026 | $144.94M | +250.1% | +81.2% | 73.0% | |
| Mar 2026 | -$58.13M | -275.6% | — | 23.8% | |
| Mar 2026 | -$229M | -251.4% | — | 17.7% | |
| Peer median (excluding OVID) | $234.64M | -2.9% | +44.1% | 82.9% | |
Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 187.8M | 44.87M | 27.04M | 26.3M | 13.15M |
| Short-term Investments | 0 | 84.13M | 78.79M | 26.77M | 56.48M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2.68M | 1 | 1K | 0 | 20.81M |
| Total Current Assets | 190.48M | 131.38M | 109.6M | 55.94M | 90.45M |
| Property, Plant & Equipment (Net) | 242.76K | 16.07M | 14.66M | 13.23M | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 164K | 222.1K | 200K | 92K | 0 |
| Long-term Investments | 3.56M | 5.62M | 17.63M | 20.97M | 64.7M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 96.13K | 1.97M | 1.94M | 1.93M | (4.22M) |
| Total Non-current Assets | 4.07M | 23.89M | 34.43M | 36.23M | 60.49M |
| Total Assets | 194.54M | 155.27M | 144.03M | 92.17M | 150.93M |
| Account Payables | 7.13M | 1.95M | 3.7M | 3.19M | 1.96M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.91M | 0 | 0 | 1K | 0 |
| Total Current Liabilities | 14.8M | 6.99M | 11.47M | 10.52M | 8.29M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 1 | 30M | 0 | 0 |
| Total Non-current Liabilities | 0 | 16M | 44.76M | 13.42M | 11.99M |
| Total Liabilities | 14.8M | 22.99M | 56.23M | 23.94M | 20.27M |
| Common Stock | 70.36K | 70.47K | 71K | 71K | 130K |
| Retained Earnings | (171.36M) | (225.53M) | (277.87M) | (304.3M) | (321.71M) |
| Accumulated OCI | 0 | (42.19K) | 0 | (35K) | (202K) |
| Other Stockholders Equity | 0 | (1) | 0 | (0) | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 179.75M | 132.27M | 87.8M | 68.23M | 130.66M |
| Total Debt | 0 | 16.54M | 16M | 14.76M | 13.42M |
| Net Debt | (187.8M) | (28.33M) | (11.04M) | (11.55M) | 266K |
Ovid Therapeutics Inc.
NASDAQ:OVID
Intrinsic Alpha fair value
Locked
Current Price
$2.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.